Phase 2 Ovarian Cancer Trial, Recruiting NCT06787612 Sponsor: Regeneron Pharmaceuticals Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT06787612
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer of a specific type (serous or endometrioid), confirmed by a lab test — certain types such as clear cell, mucinous, and carcinosarcoma are not included
  • Your cancer has continued to grow or spread after previous treatment, shown by scans, and you have at least one area of cancer that can be measured and has not been treated with radiation before
  • You are generally able to carry out daily activities with little to no limitation (confirm with trial site for exact fitness level required)
  • Your heart, liver, kidneys, and blood counts are working well enough to meet the trial's health requirements (confirm with trial site for exact values)
  • Your cancer is classified as "platinum-resistant," meaning it stopped responding to platinum-based chemotherapy within a certain time period (confirm with trial site for exact definition)

Who may not be able to join:

  • You have had a major surgery or serious physical injury within the 4 weeks before starting the trial
  • You have had a severe allergic reaction to antibody-based treatments, doxorubicin (a type of chemotherapy), or any ingredient used in the trial treatments
  • You currently have another cancer that is growing or needs active treatment
  • You have cancer that has spread to your brain or the lining around your brain and it has not been treated or is still active (confirm with trial site for specific details)
  • You have an uncontrolled infection, including HIV, hepatitis B, or hepatitis C, or a condition that weakens your immune system
  • You have a moderate to large build-up of fluid in your abdomen (confirm with trial site for exact definition)
  • You have had a bowel blockage in the last 3 months, or you currently need to receive nutrition directly into your veins

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals

Phone: 844-734-6643

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Regeneron Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
28 May 2025
Est. completion
30 October 2028

Where this trial is recruiting

🇨🇦 Canada 🇰🇷 South Korea 🇹🇼 Taiwan Turkey (Türkiye) 🇺🇸 United States

Primary endpoints

Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov